According to Gram Research analysis, a 2026 study found that a protein called semaphorin 3C (SEMA3C) directly causes kidney scarring and inflammation in adenine-induced kidney disease. When researchers removed this protein from kidney cells in mice, kidney scarring and inflammation decreased significantly. However, the protein didn’t contribute to diabetic kidney disease, suggesting that blocking SEMA3C could help only certain kidney disease patients.
Scientists discovered that a protein called semaphorin 3C (SEMA3C) plays an important role in kidney damage and scarring. Using genetically modified mice, researchers found that when they removed this protein from kidney cells, the mice had less kidney damage and inflammation from a specific type of kidney disease. However, the protein didn’t seem to matter in diabetic kidney disease. This finding could help doctors develop new treatments to prevent kidney scarring and slow down chronic kidney disease in certain patients.
Key Statistics
A 2026 research article published in Kidney360 found that mice with SEMA3C removed from kidney cells showed markedly reduced fibrosis and inflammation compared to control mice in adenine-induced tubulointerstitial nephritis.
According to the 2026 study, SEMA3C expression was highly elevated in human kidney tissue from patients with tubulointerstitial nephropathy, particularly in the proximal tubule cells.
The research demonstrated that SEMA3C stimulation of kidney fibroblasts induced profibrotic marker expression and cell proliferation, establishing the protein’s direct role in kidney scarring.
In contrast to adenine-induced disease, the 2026 study found that SEMA3C removal provided no benefit in diabetic kidney disease models, with neither proteinuria nor fibrosis being ameliorated.
The Quick Take
- What they studied: Whether a protein called SEMA3C causes kidney scarring and damage in chronic kidney disease
- Who participated: Laboratory mice with genetically modified kidneys, plus human kidney tissue samples from patients with kidney disease
- Key finding: When scientists removed SEMA3C from kidney cells in mice with adenine-induced kidney damage, the mice developed significantly less scarring and inflammation compared to normal mice
- What it means for you: This research could eventually lead to new drugs that block SEMA3C to prevent kidney scarring, but only for certain types of kidney disease—not all types respond the same way
The Research Details
Researchers used two main approaches to study SEMA3C. First, they examined kidney tissue from humans and mice using special staining techniques to see where SEMA3C was located. Second, they created genetically modified mice where they could turn off the SEMA3C gene specifically in kidney cells using a technique called CRISPR-Cas9. This allowed them to see what happened when SEMA3C was removed.
They tested these modified mice using two different models of kidney disease. The first model used a chemical called adenine to damage the kidneys in a way that mimics human kidney disease. The second model combined a high-fat diet with a chemical called streptozotocin to create diabetic kidney disease. By comparing the modified mice to normal mice, they could determine whether SEMA3C was actually causing the kidney damage.
In the laboratory, they also grew kidney cells in dishes and exposed them to different chemicals to see how SEMA3C levels changed under various conditions, helping them understand when and why this protein is produced.
This research approach is important because it goes beyond just observing that SEMA3C is present in damaged kidneys—it actually proves that SEMA3C causes the damage. By removing the protein and seeing improvement, scientists can be confident that blocking this protein could be a real treatment strategy. Testing in two different disease models shows whether the finding applies broadly or only to specific types of kidney disease.
This study used well-established laboratory techniques and disease models that are widely accepted in kidney research. The use of genetically modified mice allows for precise control and clear cause-and-effect conclusions. However, because this research was done in mice and laboratory cells rather than humans, the results need to be confirmed in human studies before becoming a treatment. The study was published in Kidney360, a peer-reviewed journal focused on kidney disease research.
What the Results Show
When researchers examined kidney tissue, they found that SEMA3C was highly expressed (produced in large amounts) in the kidney’s proximal tubules—the part of the kidney that filters waste. This was especially true in human kidney tissue from patients with tubulointerstitial nephritis, a type of kidney inflammation and scarring.
In mice with adenine-induced kidney damage, normal mice showed increased SEMA3C production, which correlated with kidney scarring and inflammation. However, mice with the SEMA3C gene removed from their kidney cells showed markedly reduced scarring and inflammation. This demonstrates that SEMA3C directly contributes to kidney damage in this type of disease.
When researchers exposed kidney cells in dishes to inflammatory chemicals (TNF-α or TGF-β), SEMA3C production increased. When they stimulated kidney fibroblasts (cells that cause scarring) with SEMA3C, these cells became more active and produced more scarring markers. This shows the mechanism: SEMA3C triggers cells to create scarring.
Interestingly, the results were different in the diabetic kidney disease model. In mice with diabetes-induced kidney damage, SEMA3C levels actually decreased rather than increased. When researchers removed SEMA3C from these diabetic mice, it didn’t improve kidney function or reduce scarring. This suggests that SEMA3C plays different roles in different types of kidney disease—it’s harmful in adenine-induced damage but may not be the main problem in diabetic kidney disease.
SEMA3C was previously known to be important for normal kidney development during fetal growth, but its role in adult kidney disease was unclear. This study is the first to demonstrate that SEMA3C actively promotes kidney scarring in a specific type of chronic kidney disease. The finding that SEMA3C’s role differs between disease types adds nuance to our understanding—it shows that blocking one protein won’t necessarily help all kidney disease patients equally.
The main limitation is that all experiments were performed in mice and laboratory cells, not in humans. Mouse models don’t always perfectly replicate human disease. The study doesn’t specify exactly how many mice were used in each experiment. Additionally, the research focused on SEMA3C’s role in kidney cells but didn’t fully explore all the ways this protein might affect other cells in the kidney. Finally, while the study shows that removing SEMA3C helps in one disease model, it doesn’t test whether blocking SEMA3C with a drug would work—only genetic removal was tested.
The Bottom Line
Based on this research, future drug development should focus on creating medications that block SEMA3C specifically for patients with adenine-induced or similar tubulointerstitial kidney disease. However, these treatments would likely not help diabetic kidney disease patients. This research is still in early stages—it’s not yet ready for human use. Confidence level: Moderate for adenine-induced disease; Low for broader application.
This research is most relevant to patients with tubulointerstitial nephritis and kidney specialists developing new treatments. It’s less relevant for diabetic kidney disease patients at this time. Anyone with chronic kidney disease should continue following their doctor’s current treatment recommendations, as this research hasn’t yet led to approved medications.
This is fundamental research that explains how kidney disease develops. It typically takes 5-10 years of additional research before laboratory discoveries become actual medications available to patients. Don’t expect SEMA3C-blocking drugs to be available soon, but this discovery provides a promising direction for future treatment development.
Frequently Asked Questions
What is semaphorin 3C and why does it matter for kidney health?
Semaphorin 3C (SEMA3C) is a protein produced by kidney cells that, according to 2026 research, promotes kidney scarring and inflammation in certain types of kidney disease. Blocking this protein could potentially slow kidney damage progression in patients with tubulointerstitial nephritis.
Does blocking SEMA3C help all types of chronic kidney disease?
No. The 2026 Kidney360 study found that SEMA3C blocking helped adenine-induced kidney disease but didn’t improve outcomes in diabetic kidney disease, showing that treatment effectiveness depends on the specific type of kidney disease.
When will SEMA3C-blocking drugs be available for patients?
This research is still in early laboratory stages. It typically takes 5-10 years of additional research before laboratory discoveries become approved medications. Patients should continue following their doctor’s current treatment recommendations.
How did researchers prove SEMA3C causes kidney damage?
Scientists used genetically modified mice where they removed the SEMA3C gene from kidney cells. These mice developed significantly less kidney scarring and inflammation than normal mice, proving SEMA3C directly causes the damage.
What should kidney disease patients do with this information?
Continue following your nephrologist’s current treatment plan and medication regimen. This research is promising for future treatments but hasn’t yet led to new approved medications. Discuss this study with your doctor if you have tubulointerstitial nephritis.
Want to Apply This Research?
- Users with chronic kidney disease should track their kidney function markers (creatinine levels and GFR) every 3 months as recommended by their doctor, noting any changes in kidney function over time
- Set reminders to take prescribed kidney medications consistently and log any symptoms of kidney problems (swelling, fatigue, changes in urination) to discuss with your healthcare provider
- Create a long-term kidney health dashboard tracking quarterly lab results, blood pressure readings, and medication adherence to identify trends and share with your nephrologist
This article summarizes laboratory research in mice and does not represent approved medical treatment. SEMA3C-blocking medications are not yet available for human use. If you have chronic kidney disease, consult your nephrologist before making any changes to your treatment plan. This research is preliminary and requires further human studies before clinical application. Always follow your doctor’s recommendations for kidney disease management.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.